Run Like Hell

Until The Cincinnati Bell Run Like Hell XVIII

Run Like Hell Store

Be A Sponsor

2008 Sponsors

Cincinnati Bell Fleet Feet Sports Mizuno Barefoot WEBN Oxford Physical Therapy Norton Cystic Fibrosis Foundation Noramtec Consultants Inc. Budweiser CityBeat Messer Gliers Goetta Cappel's Panera Vitamin Water Forehead Rumpke Road ID Snickers Marathon Energy Bar Alias Imaging Cincy Chic
Xavier University  •  Walnut Hills Cemetery
Fredrick's Landscaping  •  Fresh Sausage Specialty
A&A Safety  •  Tyson Chicken  •  Chiquita

Run for their lives.

All proceeds benefit the Cystic Fibrosis Foundation—a donor-supported, nonprofit organization determined to assure the development of the means to cure and control; cystic fibrosis (CF),

CF a scary, life-threatening genetic disease that affects the lungs and digestive systems of over 30,000 people in the U.S. But what’s more scary is that more than 14 million Americans are symptomless carriers of the defective CF gene.

The Foundation

The CF Foundation, named as one of the most efficient charities in the United States by Forbes magazine, is a donor-supported, nonprofit organization and is committed to improving the lives of those with the disease, finding new therapies and ultimately a cure.

When the CF Foundation was established in 1955, few children with cystic fibrosis lived to attend elementary school. Today, because of Foundation-supported research and care, people with CF are living to a median survival age of 37 years old, and of all of those diagnosed with CF 43% are age 18 or older. But there is still much work to be done as we continue to lose precious lives to this devastating disease.

The Foundation is making history. For the first time in the history of the disease, there are therapies in the Foundation's drug development pipeline that address the basic defect in CF (a faulty protein). If successful, these therapies could add decades of life for people with the disease. Early results in the clinical trial for VX-770, an oral drug aimed at addressing the basic defect in CF show that the compound significantly improves several key indicators of the disease--the most promising results the Foundation has seen from a Phase 2 trial.